Jinju Biomedicine
Latest round
- Series A
Last raised
- Nov 2025
Total raised
- Undisclosed
Investors
- 1
About Jinju Biomedicine
Founded in 2024 and based in Nanjing, China, Jinju Biomedicine operates as an innovative biotechnology company specializing in stem cell therapy platforms. The company provides stem cell injection products and regenerative medicine solutions for multiple therapeutic areas, including orthopedics, cardiovascular diseases, pulmonary hypertension, and aesthetic anti-aging treatments. The company works with healthcare institutions and research partners to develop stem cell injection products and therapy platforms. Its offerings include minimally invasive stem cell treatments for musculoskeletal and cardiovascular conditions, as well as anti-aging and aesthetic applications. The company’s revenue is generated by developing and commercializing stem cell therapy products and providing related clinical services.
Who invested in Jinju Biomedicine
1 investor across 1 round
See all investors in Jinju Biomedicine
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 19, 2025
Amount
Undisclosed
Investors
Questions about Jinju Biomedicine
Who invested in Jinju Biomedicine?
Jinju Biomedicine has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Jinju Biomedicine raised?
Jinju Biomedicine has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Jinju Biomedicine last raise money?
Jinju Biomedicine's most recent round on record is a Series A, in Nov 2025.
What does Jinju Biomedicine do?
Founded in 2024 and based in Nanjing, China, Jinju Biomedicine operates as an innovative biotechnology company specializing in stem cell therapy platforms.
Where is Jinju Biomedicine headquartered?
Jinju Biomedicine is headquartered in Nanjing, China.
Which VCs invest in companies like Jinju Biomedicine?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Jinju Biomedicine's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Jinju Biomedicine? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.